Table 2. Select Clinical Outcomes According to Predominant or Uniform Type I and Type II Morphologic Subtype.
| Characteristic | Predominant morphologic subtype | Uniform morphologic subtype | ||||
|---|---|---|---|---|---|---|
| Type I (n = 57) | Type II (n = 37) | P value | Type I (n = 48) | Type II (n = 23) | P value | |
| Response to NACT, No. (%) | ||||||
| Excellent | NA | NA | NA | 17 (63) | 3 (38) | .25 |
| Poor | NA | NA | 2 (7) | 2 (25) | ||
| Nonclassifiable | NA | NA | 8 (30) | 3 (38) | ||
| PIV, No. (%) | ||||||
| <8 | 27 (47) | 25 (68) | .05 | 22 (46) | 19 (83) | .004 |
| ≥8 | 30 (53) | 12 (32) | 26 (54) | 4 (17) | ||
| Postlaparoscopy treatment, No. (%) | ||||||
| NACT | 32 (56) | 18 (49) | .48 | 27 (56) | 8 (35) | .09 |
| pTRS | 25 (44) | 19 (51) | 21 (44) | 15 (65) | ||
| TRS, No. (%) | ||||||
| Not performed | 4 (7) | 2 (5) | .84 | 4 (8) | 1 (4) | .28 |
| Primary | 25 (44) | 19 (51) | 21 (44) | 15 (65) | ||
| Interval | 28 (49) | 16 (43) | 23 (48) | 7 (30) | ||
| Operative time, min | ||||||
| No. | 52 | 35 | .02 | 43 | 20 | .03 |
| Mean (SD) | 330 (110) | 400 (133) | 333 (113) | 408 (130) | ||
| Median (range) | 326 (140-711) | 393 (222-717) | 322 (140-711) | 396 (222-717) | ||
| Estimated blood loss, mL | ||||||
| No. | 52 | 35 | .001 | 43 | 22 | .006 |
| Mean (SD) | 406 (492) | 717 (673) | 415 (527) | 639 (559) | ||
| Median (range) | 250 (50-2250) | 500 (75-3000) | 200 (50-2250) | 475 (75-2500) | ||
| TRS status, No. (%) | ||||||
| Complete | 42 (81) | 29 (83) | .60 | 34 (79%) | 18 (82) | .64 |
| Optimal | 4 (8) | 4 (11) | 4 (9%) | 3 (14) | ||
| Suboptimal | 6 (12) | 2 (6) | 5 (12%) | 1 (5) | ||
| Length of stay, d | ||||||
| No. | 52 | 35 | .03 | 43 | 22 | .08 |
| Mean (SD) | 6.1 (6.7) | 7.8 (7.6) | 6.4 (7.2) | 6.8 (4.8) | ||
| Median (range) | 4.0 (0.0-34.0) | 6.0 (2.0-43.0) | 4.0 (0.0-34.0) | 6.0 (2.0-25.0) | ||
Abbreviations: NA, not applicable; NACT, neoadjuvant chemotherapy; PIV, predictive index value; pTRS, primary tumor reductive surgery; TRS, tumor reductive surgery.